Arcturus Therapeutics (ARCT) PT Lowered to $102 at Brookline Capital Markets; Sees Weakness as Buying Opportunity
Tweet Send to a Friend
Brookline Capital Markets analyst Kumaraguru Raja lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $102.00 (from $172.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
